ATPHARMA
ActiveSummary
ATPHARMA has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €198,351 and a net result of €55,503. Equity is growing by about 9.4% per year across the filed financial years. Its solvency ranks better than 24% of 21,110 sector peers (NACE 62, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
30-04
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
30-09
Financial
Equity above €150,000equity €198,351 ▲38.9%
A profit in every financial year since 2018 builds equity to €198,351.
06-05
NBB filing
Annual accounts filed
financial year 2024 · micro format · 6 days late
2024
14-06
NBB filing
Annual accounts filed
financial year 2023 · micro format · 45 days late
2023
26-04
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
30-09
Financial
Highest result from 2018 to 2025net €57,403 ▲75%
Operating result €90,449, net result €57,403, both a record.
2021
26-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
23-06
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
31-12
Financial
Equity above €100,000equity €100,467 ▲29.4%
A profit in every financial year since 2018 builds equity to €100,467.
19-09
NBB filing
Annual accounts filed
financial year 2018 · micro format · 50 days late
2018
31-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 31 days late
2017
27-07
NBB filing
Annual accounts filed
financial year 2016 · micro format
2016
21-04
NBB filing
Annual accounts filed
financial year 2015 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 25 annual accounts filed, the latest 10 are here; all 25 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.